Navigation Links
Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
Date:10/19/2007

Past AAFP President Michael Fleming, MD will serve as Digital's Medical

Director for Primary Care

WAKE FOREST, N.C., Oct. 19 /PRNewswire/ -- Digital Healthcare, a Wake Forest, NC company specializing in retinal risk assessment for diabetics, announced today that Michael Fleming, M.D., F.A.A.F.P has been named Medical Director for Primary Care. In his new role, Dr. Fleming will provide Digital Healthcare advice and counsel regarding the development and direction of its products.

Dr. Fleming is a family physician in Shreveport, LA and currently serves as a founding director and as Chief Medical Officer for Antidote Education Company, a medical education provider targeting primary care physicians. Dr. Fleming is past president of the American Academy of Family Physicians, serving as President of the 94,500 member organization in 2003-2004. He has served as Speaker of the Congress of Delegates of the AAFP, and as Board Chair of the AAFP Board of Directors.

"We are thrilled to have Dr. Fleming as part of the Digital Healthcare team," said Marc Winchester, President, North America and Board Director of Digital Healthcare. "Dr. Fleming will provide us with valuable medical expertise and insights into the concerns of primary care physicians. We look forward to relying on his direction to further enhance the benefits of our Retasure solution."

"Promoting quality care is one of my major interests," said Dr. Fleming. "I have reviewed the Retasure solution extensively and believe it is a sound solution that allows primary care physicians to improve care in their offices."

The FDA-approved Retasure program provides a simple, affordable, and non-invasive solution that allows physicians to capture their patients' retinal images during a three to five minute procedure. Images are transmitted over a secure, HIPPA compliant network to an accredited reading center. A state-licensed and board certified ophthalmologist reviews the images and results are returned to the original physician within 72 hours.

There are an estimated 20 million diabetic patients in the US, but only about half have any retinal assessments, despite a high risk of diabetic retinopathy. The National Eye Institute indicates diabetic retinopathy is the leading cause of blindness among working age American adults. More than a million patients around the world have received a retinal risk assessment using Digital Healthcare software.

About Digital Healthcare

Digital Healthcare is the global leader in retinal risk assessment. They are the world's leading provider of care management programs for diabetic retinopathy. Their award-winning MS-HUG technology is used by leading hospitals and research centers including Case Western University, The Wilmer Eye Institute at The Johns Hopkins University and the United States Military. Digital Healthcare's Retasure solution offers several advantages for primary care and endocrinologist physicians and their patients: It can be operated by non-clinicians; it is non-invasive and requires no dilation; it obtains exceptionally high-quality digital images of the retina using a simple-to-operate fundus camera; it returns results quickly to the ordering physicians; and it encourages patient compliance for regular retinal assessment.


'/>"/>
SOURCE Digital Healthcare
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Oracle Corp. to help build worlds first "Digital Hospital"
2. Digital mammography proves effective
3. Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts
4. Research into Blindness Cure Goes Digital
5. Digitalis Could Be Safe In Diastolic Heart Failure
6. MDCT Compared to Digital Radiography in Orthopedic Patients
7. Digital ID Chips Implanted in Dogs to Prevent Rabies
8. Eli Lilly Releases Digital Insulin Pen
9. The Worlds First Digital Insulin Pen With a Memory Launched
10. Interactive Digital Television to Monitor Health
11. Digital Music Project Aims to Save Tibetan Folk Songs from Extinction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... asset protection and financial planning services to families and business owners in the ... aimed at supporting children with developmental disabilities. , The Lakemary Center is a ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... communications company, launched a new website for its Center for Biosimilars, announced Michael ... include the latest developments in the field of biosimilars through thought leader interaction ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse ... for a reset. The U.S. Apple Association agrees and recommends starting each day ... that contribute to heart disease. , The U.S. Apple Association – which represents apple ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... difference. Eden Activewear is a stand-out company for several differences from other mainstream ... only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has ... the Year. , Each year, Pink Elephant recognizes a new product or ... address a specific business problem or opportunity. The award highlights original innovations that were ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... 2017  Kratom leaves, from a South East ... used to prepare tea-like beverages and commercially manufactured ... annually to increase alertness, enhance well-being and occupational ... aches and pains. PinneyAssociates, review of the scientific ... FDA and DEA in determining the most appropriate ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
Breaking Medicine Technology: